Literature DB >> 10217546

Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex.

E A Harper1, N P Shankley, J W Black.   

Abstract

1. We have investigated the binding of a novel radiolabelled CCKB/gastrin receptor ligand, [3H]-JB93182 (5[[[(1S)-[[(3,5-dicarboxyphenyl)amino]carbonyl]-2-phenylethyla mino]-carbonyl]-6-[[(1-adamantylmethyl) amino]carbonyl]-indole), to sites in rat cortex membranes. 2. The [3H]-JB93182 was 97% radiochemically pure as assessed by reverse-phase HPLC (RP-HPLC) and was not degraded by incubation (150 min) with rat cortex membranes. 3. Saturation analysis indicated that [3H]-JB93182 labelled a homogeneous population of receptors in rat cortex membranes (pKD=9.48+/-0.08, Bmax=3.61+/-0.65 pmol g(-1) tissue, nH=0.97+/-0.02, n=5). The pKD was not significantly different when estimated by association-dissociation analysis (pKD=9.73+/-0.11; n=10). 4. In competition studies, the low affinity of the CCKA receptor antagonists, L-364,718; SR27897 and 2-NAP, suggest that, under the assay conditions employed, [3H]-JB93182 (0.3 nM) does not label CCKA receptors in the rat cortex. 5. The affinity estimates obtained for reference CCKB/gastrin receptor antagonists were indistinguishable from one of the affinity values obtained when a two site model was used to interpret [125I]-BH-CCK8S competition curves obtained in the same tissue (Harper et al., 1999). 6. This study provides further evidence for the existence of two CCKB/gastrin sites in rat cortex. [3H]-JB93182 appears to label selectively sites previously designated as gastrin-G1 and therefore it may be a useful compound for the further discrimination and characterization of these putative receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217546      PMCID: PMC1565918          DOI: 10.1038/sj.bjp.0702447

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Pharmacological characterization of type B cholecystokinin binding sites on the human JURKAT T lymphocyte cell line.

Authors:  M F Lignon; N Bernad; J Martinez
Journal:  Mol Pharmacol       Date:  1991-05       Impact factor: 4.436

2.  Analysis of variation in L-365,260 competition curves in radioligand binding assays.

Authors:  E A Harper; S P Roberts; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

3.  Characterization of [3H]pentagastrin binding in guinea pig gastric glands--an alternative convenient ligand for receptor binding assay.

Authors:  R S Chang; V J Lotti; M E Keegan; K A Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1986-01-29       Impact factor: 3.575

4.  [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.

Authors:  C Durieux; M Ruiz-Gayo; P J Corringer; F Bergeron; B Ducos; B P Roques
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

5.  Sodium regulation of agonist binding at opioid receptors. II. Effects of sodium replacement on opioid binding in guinea pig cortical membranes.

Authors:  L L Werling; S R Brown; P Puttfarcken; B M Cox
Journal:  Mol Pharmacol       Date:  1986-08       Impact factor: 4.436

6.  Synthesis and characterization of a new labeled gastrin ligand, 125-I-BH-[Leu15]-gastrin-(5-17), on binding to canine fundic mucosal cells and Jurkat cells.

Authors:  J C Galleyrand; A C Lima-Leite; J C Lallement; M F Lignon; N Bernad; P Fulcrand; J Martinez
Journal:  Int J Pept Protein Res       Date:  1994-10

7.  Species differences in A1 adenosine receptor/G protein coupling: identification of a membrane protein that stabilizes the association of the receptor/G protein complex.

Authors:  C Nanoff; T Mitterauer; F Roka; M Hohenegger; M Freissmuth
Journal:  Mol Pharmacol       Date:  1995-11       Impact factor: 4.436

8.  A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists.

Authors:  M Beinborn; Y M Lee; E W McBride; S M Quinn; A S Kopin
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

9.  3H-dopamine binding to rat striatal D-2 and D-3 sites: enhancement by magnesium and inhibition by guanine nucleotides and sodium.

Authors:  M W Hamblin; I Creese
Journal:  Life Sci       Date:  1982-05-03       Impact factor: 5.037

10.  Sodium regulation of agonist and antagonist binding to beta-adrenoceptors in intact and Ns-deficient membranes.

Authors:  M Minuth; K H Jakobs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

View more
  4 in total

1.  Thermodynamic analysis of ligands at cholecystokinin CCK2 receptors in rat cerebral cortex.

Authors:  E A Harper; S P Roberts; S B Kalindjian
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

3.  Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.

Authors:  E A Harper; E P Griffin; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.